4 Biotechnology Stocks to Buy Now

by Portfolio Grader | November 21, 2012 5:30 pm

The grades of four Biotechnology stocks are on the rise this week on Portfolio Grader[1]. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, Biogen Idec (NASDAQ:BIIB[2]) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Biogen Idec is a global biotechnology company that meets the needs of therapeutic care providers and recipients. In Portfolio Grader’s specific subcategory of Equity, BIIB also gets an A. For more information, get Portfolio Grader’s complete analysis of BIIB stock[3].

Celgene (NASDAQ:CELG[4]) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Celgene is a global integrated biopharmaceutical company engaged in the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. For more information, get Portfolio Grader’s complete analysis of CELG stock[5].

Myriad Genetics (NASDAQ:MYGN[6]) shows solid improvement this week. The company’s rating rises from a B to a A. Myriad Genetics develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage. Shares of MYGN have increased 17.5% over the past month, better than the 3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of MYGN stock[7].

Gentium (NASDAQ:GENT[8]) gets a higher grade this week, advancing from a B last week to a A. Gentium is a biopharmaceutical company focused on the discovery, research, development, and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. For more information, get Portfolio Grader’s complete analysis of GENT stock[9].

Louis Navellier’s proprietary Portfolio Grader[10] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[11].

Endnotes:

  1. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  2. BIIB: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BIIB
  3. For more information, get Portfolio Grader’s complete analysis of BIIB stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=BIIB
  4. CELG: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CELG
  5. For more information, get Portfolio Grader’s complete analysis of CELG stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=CELG
  6. MYGN: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=MYGN
  7. For more information, get Portfolio Grader’s complete analysis of MYGN stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=MYGN
  8. GENT: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GENT
  9. For more information, get Portfolio Grader’s complete analysis of GENT stock: https://navelliergrowth.investorplace.com/portfolio-grader/stock-report.html?t=GENT
  10. Portfolio Grader: https://navelliergrowth.investorplace.com/portfolio-grader/
  11. here: https://navelliergrowth.investorplace.com/portfolio-grader/

Source URL: https://investorplace.com/2012/11/4-biotechnology-stocks-to-buy-now-biib-celg-mygn/

Copyright ©2024 InvestorPlace unless otherwise noted.